La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Luckin Coffee a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Luckin Coffee..

Luckin Coffee (OTC:LKNCY) Azioni, Catena delle Opzioni

Luckin Coffee Inc is a China based company engaged in operation of coffee stores. It sources its Arabica coffee beans from various suppliers and engage World Barista Champion teams to design its coffee recipes. The company also has partnered with suppliers for other products such as juices and light meals.

LUCKIN COFFEE INC SP/ADR by Luckin Coffee Inc.

Luckin Coffee Inc

Earnings

Earnings Beats

Earnings Misses

News

PLUS

ePlus Q4 Adj. EPS $1.11 Beats $0.86 Estimate, Sales $498.11M Miss $523.85M Estimate

<p>Deckers Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) reported quarterly earnings of $1.00 per share which beat the analyst consensus estimate of $0.59 by 69.49 percent. This is a 20.48 percent increase over earnings of $0.83 per share from the same period last year.  The company reported quarterly sales of $1.02 billion which beat the analyst consensus estimate of $1.01 billion by 1.52 percent.  This is a 6.38 percent increase over sales of $959.76 million the same period last year.</p>


DECK

Deckers Outdoor Q4 EPS $1.00 Beats $0.59 Estimate, Sales $1.02B Beat $1.01B Estimate

WIIM

IMMX

Immix Biopharma shares are trading higher after the company announced the publication of cell therapy NXC-201 Abstract #7508, selected for oral presentation at the 2025 American Society of Clinical Oncology Annual Meeting.

<p>Cavco Indus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVCO#NASDAQ">CVCO</a>) reported quarterly earnings of $5.40 per share which beat the analyst consensus estimate of $4.87 by 10.88 percent. This is a 34 percent increase over earnings of $4.03 per share from the same period last year.  The company reported quarterly sales of $508.36 million which beat the analyst consensus estimate of $504.15 million by 0.83 percent.  This is a 21.00 percent increase over sales of $420.12 million the same period last year.</p>


CVCO

Cavco Indus Q4 Adj. EPS $5.40 Beats $4.87 Estimate, Sales $508.36M Beat $504.15M Estimate

<p><i>– NXC-201 demonstrated a complete response (CR) rate of 71% (5/7 patients) –</i></p>
<p><i>– No relapses recorded to-date; no safety signals identified –</i></p>
<p><i>– Updated results with a later data cutoff, including endpoint analysis, will be presented at ASCO by lead investigator Heather Landau, MD, of Memorial Sloan Kettering Cancer Center –</i></p>


Biotech

Events

General

Immix Biopharma Publishes And Presents Results For Cell Therapy NXC-201 Abstract #7508 At ASCO

<p>Workday (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) sees Q2 sales of $2.160 billion vs $2.34 billion analyst estimate.</p>


Guidance

WDAY

Workday Sees Q2 Sales $2.160B vs $2.34B Est

INTU

Intuit shares are trading higher after the company reported better-than-expected Q3 financial results and raised guidance.

ROST

Ross Stores Sees Q2 GAAP EPS $1.40-$1.55 vs $1.65 Est

<p>Viper Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNOM#NASDAQ">VNOM</a>) has outperformed the market over the past 5 years by 15.26% on an annualized basis producing an average annual return of 29.62%. Currently, Viper Energy has a market capitalization of $5.30 billion. </p>
<p><strong>Buying $1000 In VNOM:</strong> If an investor had bought $1000 of VNOM stock 5 years ago, it would be worth <strong>$3,659.22</strong> today based on a price of $40.46 for VNOM at the time of writing.</p>
<h3>Viper Energy's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747944295_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Trading Ideas

VNOM

If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today

<p>Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) is looking for Q2 GAAP EPS of $1.37-$1.46 vs $1.23 analyst estimate..</p>


ADSK

Autodesk Sees Q2 GAAP EPS $1.37-$1.46 vs $1.23 Est

<p>Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) lowers FY2026 GAAP EPS guidance from $4.74-$5.37 to $4.63-$5.14 vs $5.29 analyst estimate..</p>


Autodesk Lowers FY2026 GAAP EPS Guidance from $4.74-$5.37 to $4.63-$5.14 vs $5.29 Est

<p>Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) is looking for Q2 Adj EPS of $2.44-$2.48 vs $2.34 analyst estimate. sees sales of $1.720 billion-$1.730 billion vs $1.70 billion analyst estimate.</p>


Autodesk Sees Q2 Adj EPS $2.44-$2.48 vs $2.34 Est; Sees Sales $1.720B-$1.730B vs $1.70B Est

<p>Workday (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) reported quarterly earnings of $2.23 per share which beat the analyst consensus estimate of $2.01 by 10.95 percent. This is a 28.16 percent increase over earnings of $1.74 per share from the same period last year.  The company reported quarterly sales of $2.24 billion which beat the analyst consensus estimate of $2.22 billion by 0.99 percent.  This is a 12.56 percent increase over sales of $1.99 billion the same period last year.</p>


Workday Q1 Adj. EPS $2.23 Beats $2.01 Estimate, Sales $2.24B Beat $2.22B Estimate

<p>Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) raises FY2026 Adj EPS guidance from $9.34-$9.67 to $9.50-$9.73 vs $9.52 analyst estimate. Raises FY2026 sales outlook from $6.89 billion-$6.96 billion to $6.92 billion-$7.00 billion vs $6.93 billion estimate.</p>


Autodesk Raises FY2026 Adj EPS Guidance from $9.34-$9.67 to $9.50-$9.73 vs $9.52 Est; Raises FY2026 Sales Guidance from $6.89B-$6.96B to $6.92B-$7.00B vs $6.93B Est

Intuit Sees Q4 Adj EPS $2.63-$2.68 vs $2.59 Est; Sees Sales $3.723B-$3.760B vs $3.51B Est

<p>Intuit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) raises FY2025 Adj EPS guidance from $19.16-$19.36 to $20.07-$20.12 vs $19.34 analyst estimate. Raises FY2025 sales outlook from $18.16 billion-$18.35 billion to $18.72 billion-$18.76 billion vs $18.35 billion estimate.</p>


Intuit Raises FY2025 Adj EPS Guidance from $19.16-$19.36 to $20.07-$20.12 vs $19.34 Est; Raises FY2025 Sales Guidance from $18.16B-$18.35B to $18.72B-$18.76B vs $18.35B Est

Ross Stores Q1 EPS $1.47 Beats $1.44 Estimate, Sales $4.99B Beat $4.97B Estimate

<ul>
<li><i>Achieved statistically significant ≥1-stage fibrosis regression at Week 52 vs. placebo (52.85% vs. 29.84%, P=0.0002).</i></li>
<li><i>Demonstrated favorable safety and tolerability profile: 4.88% serious adverse events vs. 6.45% for placebo; zero discontinuations due to adverse events.</i></li>
<li><i>Breakthrough Therapy Designation granted by China's National Medical Products Administration ("NMPA") in 2021 supports potential first-in-class approval in CHB-associated liver fibrosis ("CHB fibrosis").</i></li>
<li><i>Gyre intends to seek accelerated approval for Hydronidone in CHB fibrosis, with a New Drug Application ("NDA") submission to the NMPA expected in Q3 2025.</i></li>
<li><i>U.S. Phase 2 trial in MASH-associated liver fibrosis expected to begin in 2H2025.</i></li>
</ul>
<p>SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GYRE#NASDAQ">GYRE</a>), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced that its lead compound, Hydronidone (F351), met the primary endpoint in a pivotal Phase 3 trial evaluating its efficacy and safety for the treatment of liver fibrosis in patients with chronic hepatitis B ("CHB") in China.</p>
<p><i>The 52-week, multicenter, double-blind, placebo-controlled trial enrolled 248 patients with CHB fibrosis across 39 hospitals in China. Patients were randomized 1:1 to receive either Hydronidone (270 mg/day, orally) or placebo, in addition to background entecavir antiviral therapy. The trial met its primary endpoint, with a statistically significant proportion of patients receiving Hydronidone achieving a ≥1-stage regression in liver fibrosis compared to placebo (P=0.0002). These results are consistent with the efficacy and safety outcomes observed in Gyre's prior Phase 2 trial.</i></p>


GYRE

Gyre Therapeutics' Hydronidone Meets Primary Endpoint In Pivotal Phase 3 Trial Evaluating Efficacy And Safety For Treatment Of Liver Fibrosis In Patients With Chronic Hepatitis B In China

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Vertiv Holdings</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with VRT, it often means somebody knows something is about to happen.</p>
<p>Today, Benzinga's options scanner spotted 10 options trades for <strong>Vertiv Holdings</strong>.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 50% bullish and 50%, bearish.</p>
<p>Out of all of the options we uncovered, there was 1 put, for a total amount of $40,000, and 9, calls, for a total amount of $360,990.</p>
<h3>Projected Price Targets</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $72.5 and $120.0 for Vertiv Holdings, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In terms of liquidity and interest, the mean open interest for Vertiv Holdings options trades today is 1015.71 with a total volume of 467.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Vertiv Holdings's big money trades within a strike price range of $72.5 to $120.0 over the last 30 days.</p>
<h3>Vertiv Holdings Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747944178_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>VRT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$18.25</td>
<td>$17.85</td>
<td>$17.93</td>
<td>$110.00</td>
<td>$89.6K</td>
<td>3.4K</td>
<td align="right">51</td>
</tr>
<tr>
<td>VRT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$8.9</td>
<td>$8.25</td>
<td>$8.41</td>
<td>$101.00</td>
<td>$42.0K</td>
<td>1</td>
<td align="right">100</td>
</tr>
<tr>
<td>VRT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$8.55</td>
<td>$7.95</td>
<td>$8.32</td>
<td>$101.00</td>
<td>$41.6K</td>
<td>1</td>
<td align="right">150</td>
</tr>
<tr>
<td>VRT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/30/25</td>
<td>$4.1</td>
<td>$4.0</td>
<td>$4.0</td>
<td>$104.00</td>
<td>$40.0K</td>
<td>36</td>
<td align="right">105</td>
</tr>
<tr>
<td>VRT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$7.9</td>
<td>$7.8</td>
<td>$7.9</td>
<td>$101.00</td>
<td>$39.5K</td>
<td>1</td>
<td align="right">150</td>
</tr>
</tbody>
</table>
</p>
<h3>About Vertiv Holdings</h3>
<p>Vertiv has roots tracing back to 1946 when its founder, Ralph Liebert, developed an air-cooling system for mainframe data rooms. As computers started making their way into commercial applications in 1965, Liebert developed one of the first computer room air conditioning, or CRAC, units, enabling the precise control of temperature and humidity. The firm has slowly expanded its data center portfolio through internal product development and the acquisition of thermal and power management products like condensers, busways, and switches. Vertiv has global operations today; its products can be found in data centers in most regions throughout the world.</p>
<p>In light of the recent options history for Vertiv Holdings, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Vertiv Holdings's Current Market Status</h3>
<ul>
<li>With a volume of 2,967,135, the price of VRT is up 1.1% at $104.75. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 62 days.</li>
</ul>
<h3>Professional Analyst Ratings for Vertiv Holdings</h3>
<p>A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $126.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from JP Morgan persists with their Overweight rating on Vertiv Holdings, maintaining a target price of $127.<br />
&#x2A; An analyst from Morgan Stanley has decided to maintain their Overweight rating on Vertiv Holdings, which currently sits at a price target of $125. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Vertiv Holdings with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


Options

Markets

Unpacking the Latest Options Trading Trends in Vertiv Holdings

<p>Financial giants have made a conspicuous bearish move on Bank of America. Our analysis of options history for Bank of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) revealed 13 unusual trades.</p>
<p>Delving into the details, we found 38% of traders were bullish, while 61% showed bearish tendencies. Out of all the trades we spotted, 7 were puts, with a value of $591,585, and 6 were calls, valued at $260,748.</p>
<h3>What's The Price Target?</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $35.0 and $44.0 for Bank of America, spanning the last three months.</p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for Bank of America options trades today is 7711.45 with a total volume of 10,550.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Bank of America's big money trades within a strike price range of $35.0 to $44.0 over the last 30 days.</p>
<h3>Bank of America 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747944172_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>BAC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$4.15</td>
<td>$4.05</td>
<td>$4.05</td>
<td>$42.00</td>
<td>$202.5K</td>
<td>4.9K</td>
<td>500</td>
</tr>
<tr>
<td>BAC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/30/25</td>
<td>$0.64</td>
<td>$0.63</td>
<td>$0.63</td>
<td>$43.00</td>
<td>$119.7K</td>
<td>1.8K</td>
<td>3.6K</td>
</tr>
<tr>
<td>BAC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/18/26</td>
<td>$6.05</td>
<td>$5.95</td>
<td>$5.95</td>
<td>$42.00</td>
<td>$91.6K</td>
<td>9.6K</td>
<td>448</td>
</tr>
<tr>
<td>BAC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$4.15</td>
<td>$4.05</td>
<td>$4.06</td>
<td>$42.00</td>
<td>$81.1K</td>
<td>4.9K</td>
<td>700</td>
</tr>
<tr>
<td>BAC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/17/25</td>
<td>$2.17</td>
<td>$2.15</td>
<td>$2.17</td>
<td>$41.00</td>
<td>$56.6K</td>
<td>754</td>
<td>390</td>
</tr>
</tbody>
</table>
</p>
<h3>About Bank of America</h3>
<p>Bank of America is one of the largest financial institutions in the United States, with more than $3.2 trillion in assets. It is organized into four major segments: consumer banking, global wealth and investment management, global banking, and global markets. Bank of America's consumer-facing lines of business include its network of branches and deposit-gathering operations, retail lending products, credit and debit cards, and small-business services. The company's Merrill Lynch operations provide brokerage and wealth-management services, as does its private bank. Wholesale lines of business include investment banking, corporate and commercial real estate lending, and capital markets operations. Bank of America has operations in several countries but is primarily US-focused.</p>
<p>In light of the recent options history for Bank of America, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Where Is Bank of America Standing Right Now?</h3>
<ul>
<li>With a trading volume of 22,941,830, the price of BAC is up by 0.43%, reaching $43.44.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 55 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Bank of America</h3>
<p>Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $51.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Oppenheimer keeps a Outperform rating on Bank of America with a target price of $51. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Bank of America options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


Comments

Luckin Coffee

Luckin Coffee (LKNCY) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO